Affordable Access

deepdyve-link
Publisher Website

Treatment for severe COVID-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis

Authors
  • Sandoval, Diego1, 2
  • Rama, Inés1, 2
  • Quero, María1, 2
  • Hueso, Miguel1, 2
  • Gómez, Francisco1, 2
  • Cruzado, Josep M1, 2
  • 1 Department of Nephrology, Hemodialysis Unit, Bellvitge University Hospital, Spain , (Spain)
  • 2 Biomedical Research Institute (IDIBELL), Hospital Duran i Reynals, Spain , (Spain)
Type
Published Article
Journal
Clinical Kidney Journal
Publisher
Oxford University Press
Publication Date
Jan 18, 2021
Volume
14
Issue
5
Pages
1475–1477
Identifiers
DOI: 10.1093/ckj/sfab010
PMID: 33953913
PMCID: PMC7929023
Source
PubMed Central
Keywords
Disciplines
  • AcademicSubjects/MED00340
License
Unknown

Abstract

Haemodialysis (HD) patients present more morbidity and mortality risk in coronavirus disease 2019 (COVID-19). In patients who may develop severe symptoms, the process called ‘viral sepsis’ seems to be a crucial mechanism. In those cases, the HD procedure provides an excellent tool to explore the benefit of some extracorporeal therapies. We reported the outcome of four HD patients with severe COVID-19 treated with Seraph®100 haemoperfusion (HP) device. Three of the four cases presented a good clinical response after HP. In conclusion, the treatment with Seraph®100 device may be a simultaneous treatment to improve HD patients with severe acute respiratory syndrome coronavirus 2.

Report this publication

Statistics

Seen <100 times